US2018015096A1PendingUtilityA1

Highly active anti-neoplastic and anti-proliferative agents

Assignee: G1 THERAPEUTICS INCPriority: Mar 15, 2013Filed: Sep 22, 2017Published: Jan 18, 2018

Est. expiryMar 15, 2033(~6.7 yrs left)· nominal 20-yr term from priority

Inventors:Jay Copeland Strum John Emerson Bisi Patrick Joseph Roberts Francis Xavier Tavares

A61P 37/06A61P 35/02A61P 37/02A61P 43/00A61P 35/00C07D 487/20A61K 47/6867A61K 51/0459A61P 17/02A61K 31/529A61P 17/10A61P 1/04A61K 51/0468A61K 31/527A61P 19/02A61K 47/545A61K 31/5377A61P 17/06C07D 487/14A61K 47/6803

63

PatentIndex Score

0

Cited by

0

References

0

Claims

Abstract

This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders.

Claims

exact text as granted — not AI-modified

We claim:

1 . A method for the treatment of psoriasis that comprises administering to a host in need thereof an effective amount of a compound selected from:

or a pharmaceutically acceptable salt thereof.

2 . The method of claim 1 , wherein the host is human.

3 . The method of claim 2 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

4 . The method of claim 2 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

5 . The method of claim 4 wherein the compound is

or a pharmaceutically acceptable salt thereof.

6 . The method of claim 2 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

7 . The method of claim 2 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

8 . The method of claim 2 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

9 . The method of claim 2 , wherein the compound is administered topically.

10 . The method of claim 2 , wherein the compound is administered in combination with a second active agent.

11 . A method for the treatment of atopic dermatitis that comprises administering to a host in need thereof an effective amount of a compound selected from:

or a pharmaceutically acceptable salt thereof.

12 . The method of claim 11 , wherein the host is human.

13 . The method of claim 12 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

14 . The method of claim 12 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

15 . The method of claim 12 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

16 . The method of claim 12 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

17 . The method of claim 12 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

18 . The method of claim 12 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

19 . The method of claim 12 , wherein the compound is administered topically.

20 . The method of claim 12 , wherein the compound is administered in combination with a second active agent.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.